NASDAQ · Financial Statements
Viking Therapeutics, Inc. (VKTX) Financial Statements
$28.51
NASDAQ: VKTX
Market Cap $3.33B
Overview Financials Dividend Viking Therapeutics, Inc. most recently reported annual revenue of $0, net profit of $-360.0M. See the full income statement, balance sheet, and cash flow statement below, plus valuation and return ratios.
Annual Financials (USD)
Metric 2021 2022 2023 2024 2025 Revenue $0 $0 $0 $0 $0 Operating Profit $-56.0M $-70.0M $-101.0M $-151.0M $-393.0M Net Profit $-55.0M $-69.0M $-86.0M $-110.0M $-360.0M EPS $-0.70 $-0.88 $-0.91 $-1.01 $-3.19 Op Margin — — — — —
Balance Sheet (USD)
Metric 2021 2022 2023 2024 2025 Total Assets $211.0M $169.0M $368.0M $908.0M $716.0M Total Liabilities $9.0M $23.0M $20.0M $28.0M $77.0M Cash $26.0M $37.0M $56.0M $27.0M $166.0M Borrowings $0 $2.0M $1.0M $1.0M $0
Cash Flow (USD)
Metric 2021 2022 2023 2024 2025 Operating Cash Flow $-48.0M $-48.0M $-73.0M $-88.0M $-279.0M Investing Cash Flow $38.0M $55.0M $-179.0M $-553.0M $341.0M Financing Cash Flow $-1.0M $6.0M $2.0M $15.0M $74.0M Net Cash Flow $-3.0M $10.0M $19.0M $-29.0M $139.0M Free Cash Flow $-48.0M $-48.0M $-73.0M $-88.0M $-279.0M
Valuation & Return Ratios
Metric Value PEG Ratio 0.08 EV / EBITDA -6.72 FCF Yield -11.28% Quick Ratio 4.72 Interest Coverage -70002.62 Return 1Y 16.61% Return 3Y 132.20% Return 5Y 444.78%
Screens featuring this stock